Aptorum Group Ltd Class A (NASDAQ:APM) — Market Cap & Net Worth
Market Cap & Net Worth: Aptorum Group Ltd Class A (APM)
Aptorum Group Ltd Class A (NASDAQ:APM) has a market capitalization of $5.59 Million ($5.59 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28139 globally and #5545 in its home market, demonstrating a -4.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aptorum Group Ltd Class A's stock price $0.88 by its total outstanding shares 6346823 (6.35 Million). Analyse Aptorum Group Ltd Class A cash conversion from operations to see how efficiently the company converts income to cash.
Aptorum Group Ltd Class A Market Cap History: 2018 to 2026
Aptorum Group Ltd Class A's market capitalization history from 2018 to 2026. Data shows change from $963.45 Million to $5.59 Million (-49.89% CAGR).
Index Memberships
Aptorum Group Ltd Class A is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #829 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2662 of 3165 |
Weight: Aptorum Group Ltd Class A's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aptorum Group Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aptorum Group Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
36.03x
Aptorum Group Ltd Class A's market cap is 36.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $963.45 Million | $383.45K | -$14.83 Million | 2512.58x | N/A |
| 2019 | $1.01 Billion | $535.17K | -$18.69 Million | 1879.73x | N/A |
| 2020 | $156.77 Million | $911.51K | $7.07 Million | 171.99x | 22.18x |
| 2021 | $95.20 Million | $1.54 Million | -$25.05 Million | 61.74x | N/A |
| 2022 | $34.91 Million | $1.30 Million | -$9.80 Million | 26.94x | N/A |
| 2023 | $15.54 Million | $431.38K | -$2.83 Million | 36.03x | N/A |
Competitor Companies of APM by Market Capitalization
Companies near Aptorum Group Ltd Class A in the global market cap rankings as of May 4, 2026.
Key companies related to Aptorum Group Ltd Class A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Aptorum Group Ltd Class A Historical Marketcap From 2018 to 2026
Between 2018 and today, Aptorum Group Ltd Class A's market cap moved from $963.45 Million to $ 5.59 Million, with a yearly change of -49.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.59 Million | -16.98% |
| 2025 | $6.73 Million | -62.14% |
| 2024 | $17.77 Million | +14.35% |
| 2023 | $15.54 Million | -55.49% |
| 2022 | $34.91 Million | -63.33% |
| 2021 | $95.20 Million | -39.27% |
| 2020 | $156.77 Million | -84.42% |
| 2019 | $1.01 Billion | +4.41% |
| 2018 | $963.45 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Aptorum Group Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.59 Million USD |
| MoneyControl | $5.59 Million USD |
| MarketWatch | $5.59 Million USD |
| marketcap.company | $5.59 Million USD |
| Reuters | $5.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aptorum Group Ltd Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small mol… Read more